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Summary  
Neglected Tropical Diseases (NTDs) represent one of the biggest health challenges in tropical and 
subtropical countries. They are most commonly caused by helminths, including the soil-
transmitted helminths (STH) (Ascaris lumbricoides, Trichuris trichiura, Ancylostoma duodenale and 
Necator americanus), Schistosoma spp (S. haematobium, S. mansoni, S. japonicum being the most 
common) and Strongyloides stercoralis.   
Helminth infections are widely distributed but prevalence is highest in low-resource settings in 
subSaharan Africa, the Americas and Asia. Helminthic infections are more common in children, 
and, when chronic may be responsible for severe morbidities that interfere with normal growth 
and cognitive development. Preventive chemotherapy (PC) is the main strategy promoted by the 
World Health Organization to control morbidities linked to NTDs. This intervention is based on 
regular anthelminthic treatment of in-need populations in endemic areas.  
Diagnostic methods for the detection of these infections suffer from low sensitivity and new 
approaches, such as molecular techniques, that may improve sensitivity, often are not applicable 
in field laboratories where expensive tools are not affordable.   
The treatment of NTDs relies on few drugs: benzimidazoles (albendazole and mebendazole) for 
STH, praziquantel for schistosomiasis and ivermectin for onchocerciasis, lymphatic filariasis and 
strongyloidiasis. PC programs are highly effective but the regular use of the few available drugs in 
a vast population raises concern regarding development of resistance. Although confirmed 
resistance has not yet been proved, a lower sensitivity to praziquantel has been reported in 
populations who received several rounds of PC. Additionally, benzimidazoles are scarcely effective 
against T. trichiura. Therefore, there is a great need of new effective drugs to tackle these 
infections.  
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In the frame of my PhD program, I addressed the need of developing new drugs against helminthic 
infections by testing the efficacy of moxidectin, a macrocyclic lactone used in veterinary medicine, 
against STH, S. haematobium, S. mansoni, and S. stercoralis in exploratory randomized Phase 2 
trials.  We confirmed its good efficacy against S. stercoralis but not against Schistosoma spp. In our 
randomized non-inferiority Phase 2 clinical trial conducted with different drug combinations, 
moxidectin in co-administration with albendazole showed a good efficacy against STH infections. 
From a diagnostic point of view, we assessed the sensitivity of two DNA extraction methods for the 
detection of S. stercoralis using PCR; this technique showed a good potential but further studies 
are still necessary to improve its standardization. We also conducted an ultrasound assessment of 
the impact of different doses of praziquantel on urinary tract morbidity in S. haematobium 
infected children versus placebo. We found that light and moderate bladder morbidity has an early 
onset, and is present in pre-school-aged children. Six months after treatment we registered 90% of 
regression of morbidity in treated children and only 10% in the placebo group.   
Our findings contribute to the development of moxidectin against helminthic infections. Our 
findings indicate that this drug is worth further evaluations before it can be promoted for public 
health campaigns. Furthermore, our data might foster the development of new potential 
diagnostics for NTDs such as S. stercoralis. Eventually, we confirmed the relevance of PC for the 
control of morbidity due to urogenital schistosomiasis that can be assessed in the field by 
relatively simple tools such as ultrasound.   
    
Table of abbreviations  
CCA  Circulating cathodic antigen   
CI  Confidence interval  
CR  Cure rate  
DALYs   Disability-adjusted life years  
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EKBB  Ethical committee of Basel  
ELISA  Enzyme-linked immunosorbent assay  
EPG  Eggs per gram of stool  
ERR  Egg reduction rate  
ID  Identification number  
IHA  Indirect hemagglutination  
ITT  Intention-to-treat  
LAMP  Loop-mediated isothermal amplification  
MDG  Millennium development goal  
N (or n)  Sample size  
NVP  Negative predictive value  
NTD  Neglected tropical disease  
OR  Odds ration  
PCR  Polymerase chain reaction  
PHL-IdC  Public Health Laboratory-Ivo de Carneri  
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qPCR  Real-time quantitative PCR  
SD  Standard deviation  
STH  Soil-transmitted helminth  
Swiss TPH  Swiss Tropical and Public Health Institute  
WHO  World Health Organization  
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1. Epidemiology of soil-transmitted helminthiasis and 
schistosomiasis  
Intestinal parasitic infections represent one of the biggest health challenges in tropical and subtropical 
countries [1]. The most common soil-transmitted helminths (STH) are the large roundworm (Ascaris 
lumbricoides), the whipworm (Trichuris trichiura), and the hookworms (Ancylostoma duodenale and 
Necator americanus). Another common intestinal parasite, but conventionally not named together with the 
other STH, is the dwarf threadworm Strongyloides stercoralis [1].   
Soil transmitted helminthiasis and schistosomiasis (introduced below) are grouped among the neglected 
tropical diseases also because they thrive with poverty, and people who suffer from these diseases are 
mostly the poorest who  live in mid-low resource settings [2–5].   
According to WHO estimates from 2015, almost 2 billion people are affected by STH infections , of which 
875 million children are in need of regular treatment [1,6,7]. Approximately 270 million preschool-aged 
children (PSAC) and more than 550 million school-aged children live in areas where these parasites are 
extensively transmitted [7]. Approximately 250 million girls and women of child bearing age (WCBA) are 
living in areas that are endemic for STH. Infections are widely distributed in all WHO regions, with the 
greatest numbers occurring in sub-Saharan Africa, the Americas and Asia. Overall, more than 100 countries 
are endemic for  
STH infections [7]. This estimate excludes S. stercoralis, which alone infects up to 300 million people globally  
[4].   
The number of years of healthy life lost attributable to a disease (or group of diseases) (known as Disability 
Adjusted Life Years: DALYs) is used as a measure of disease burden and provides a comparative indication of 
the importance of the disease in public health. For intestinal and urogenital parasitic infections this 
calculation is particularly cumbersome, as they often occur asymptomatic or with generic symptoms [3,8,9]. 
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For STH it has been estimated that overall DALYs have decreased from 5 million in the 1990 to 
approximately  
3 million in the past decades [8,10,11]. The same trend has been observed in case of schistosomiasis, with a 
previewed halving of DALYS (1.5 million to 750 000) in the upper-middle income countries. The slower 
adoption and implementation of recommended control strategies in the lowest income group may be 
related to multiple interrelated factors, including lack of human and financial resources, weak health 
systems, and epidemiological factors [10].   
Schistosomiasis is a disease caused by the fluke of the genus Schistosoma, which is endemic in many 
tropical and subtropical countries. It is estimated that globally more than 770 million people are infected by 
at least one Schistosoma species (the most represented are: S. mansoni, S. haematobium, S. intercalatum, 
S. japonicum) [2,7]. As observed for STH, Schistosoma spp have similar high-risk population groups, being 
more prevalent among PSAC and SAC living in endemic countries and having limited access to clean water 
and sanitation [12].  
The epidemiology of S. stercoralis is slightly different, being spread among different age ranges. Its life-
cycle, as described below, differs slightly from the one of other STHs, being characterized by autoinfection, 
that leads to life-long carriage of the parasite, if untreated [13,14]. S. stercoralis is also called the neglected 
of the neglected tropical diseases [5], as few data are available on its prevalence and linked morbidity; 
actually, the true prevalence of this parasite is not well known and is often underestimated [5,13]. Similarly 
to the other intestinal parasites, S. stercoralis infection is mostly asymptomatic or characterized by 
unspecific symptoms  
(diarrhoea, abdominal cramps, urticaria), and the diagnostic tools available for its detection are not 
accurate [5,15].  
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Fig 1. Prevalence by global regions of (A) Ascaris lumbricoides (for 2010), (B) 
Trichuris trichiura (for 2010), (C) hookworm (Necator americanus and Ancylostoma 
duodenale; for 2010), and (D) Strongyloides stercoralis (for 2011)  
  
  
  
Fig 2. Prevalence of schistosomiasis, WHO 2015    
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2. Life cycle  
2.1 Soil transmitted helminths  
Eggs of STH are released through stools and contaminate the environment during open air defecation. In 
warm and moist soil, eggs can remain viable for years. Helminth eggs need a period of maturation in the 
soil (variable from weeks to months) before becoming infective. Infection of the host occurs through 
ingestion of infective eggs (either by eating raw and contaminated vegetables/ fruits or by ingestion of soil 
in the case of children). In the case of hookworm, free living larvae can infect people by penetrating 
unwounded skin, especially in areas were bare-foot walking is common practice. After ingestion, A. 
lumbricoides eggs disclose the larvae, which penetrate the intestinal mucosa and migrate to the lung 
circulation. Third stage larvae pass through tracheobronchial tree to the larynx, are swallowed and settle 
into the small intestine.   
T. trichiura has a simpler life cycle. After infection, T. trichiura eggs hatch, worms develop and migrate first 
into the small intestine, and afterwards adult worms attach to the villi in the large intestine (caecum and 
ascending colon).   
After penetration hookworm larvae are transported via the blood stream to the pulmonary circle, from 
where they pass into the larynx, are swallowed, and move into the small intestine. Adult worms can survive 
for months or even years in the host.   
2.2 Strongyloides stercoralis   
The life cycle of S. stercoralis is more complex compared to STH. This parasite has a free-living form which 
develops outside the human host. The larvae of S. stercoralis infect the host by penetrating unwounded 
skin or by being ingested. They are then transported to the pulmonary cycle, pass to the larynx and enter 
the small intestine. The adult worms lodge in the duodenal and jejunal, where they lay eggs that hatch 
within the human intestine and produce two kinds of larvae. The rhabditiform larvae migrate to the lumen 
and are released with faeces, whereas, the filariform larvae penetrate the intestinal wall or perianal skin, 
re-enter a new cycle and disseminate to different organs. Rhabditiform larvae can contaminate the 
environment and transform into infective filariform larvae or perpetuate a free-living cycle outside the host.   
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Fig 3. Life cycle STH and S. stercoralis   
    
2.3 Schistosomes  
Schistosome eggs are passed in stools or urine of infected individuals (depending on whether they are 
infected by intestinal or urogenital schistosomiasis) and need contact with fresh water for their 
development. In water, they transform into mobile miracidia that infect snail intermediate hosts (specific 
snails for each Schistosoma species). Miracidia multiply in the snails which release thousands of mobile 
infective larvae with forked tails, named cercariae. Cercariae infect human hosts by penetrating the skin 
into fresh water. After penetration, the parasite migrates through the lungs and develops into 
schistosomula (maturing larvae) that settle in the liver. After a few weeks, they migrate via the blood 
stream to their destinations which are either the perivesicular veins (S. haematobium) or the mesenteric 
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veins (S. mansoni, japonicum, intercalatum and others). Adult worms live in copula and the female only 
moves to release the eggs. Eggs penetrate the blood vessels, then the intestinal or bladder mucosa with the 
spike and reach fresh water through urine or stool.   
  
Fig 4. Life cycle of Schistosoma spp    
3. Diagnosis  
3.1 Direct methods  
The diagnosis of intestinal parasites has always been cumbersome, with the most commonly used methods 
being burdened by low accuracy and sensitivity [16]. Moreover, intestinal parasites do not release eggs at a 
constant rate, therefore more than one sample on different collection days is needed in order to increase 
the accuracy of diagnosis. Up-to-date, there is no “gold standard” for the diagnosis of intestinal helminths 
infections; therefore, there is no clear indication on which is the best method to use.   
In endemic countries, referral hospitals and laboratories at individual level diagnose these infections via a 
direct smear from fresh stool samples [17]. In settings were a centrifuge is available, samples are mixed 
with formalin and ether (to clean the sample from debris), centrifuged and the pellet is analysed on a slide 
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(formolether concentration method) [17,18]. These techniques allow the detection of all intestinal 
helminths and protozoa, but no indication on the intensity of infection (eggs per grams (EPG)) is given.   
If public health trials or evaluations are conducted, direct, qualitative methods are inadequate and not 
reliable. The vast majority of trials focus on prevalence and intensity of infections, comparison of different 
diagnostic techniques and evaluation of drug efficacy. For such results to be obtained, more sophisticated 
and reliable techniques are needed. In drug efficacy trials it is crucial that quantitative methods are applied, 
especially when the egg reduction rate (ERR) is under evaluation. The ideal diagnostic method applied on 
the field must be fast, accurate, easy to use also in low resource settings and in trials where a large number 
of samples are screened.   
Currently, the recommended quantitative method for the detection of STH and schistosomes is the 
duplicate Kato-Katz [19] ideally on two stool samples [18]. It is a quantitative method that allows counting 
eggs and classifying the infection intensity according to WHO classification (light, moderate or heavy). This 
method shows reasonable sensitivity at a high intensity of infection [18], however it loses sensitivity and 
reliability at low intensity infections [16,20]. An important advantage of this method is that it is cheap and 
the equipment required to perform it is easily available [21,22]. In order to enhance its sensitivity, multiple 
examination of the same sample and, ideally, multiple sampling on different days are performed [23,24].   
Other diagnostic methods have been recently developed in order to increase sensitivity and overcome the 
Kato-Katz’s limitations. The FLOTAC and Mini-FLOTAC are novel tools based on the principle of flotation 
techniques used in veterinary medicine and adapted to human samples [17]. Both are quantitative methods 
that detect intestinal helminths and protozoa infections [16,17,21,25]. The FLOTAC has proved to have a 
higher sensitivity, especially at low intensity infections, mainly due to the fact that the eggs are separated 
from the faecal material through centrifugation and the slide is easier to read than those prepared with the 
Kato-Katz method [26–28]. The biggest limitation of the application of the FLOTAC in field studies is 
represented by the required equipment, which is not available in peripheral laboratories and is rather 
expensive [29]. The Mini-FLOTAC is a simpler device developed from the FLOTAC philosophy but more 
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affordable at field level [30]. This technique is faster, as sensitive as the Kato Katz and cheaper than the 
FLOTAC technique [18]. In a field evaluation of Mini-FLOTAC and Kato-Katz, it was demonstrated that the 
former detected higher  mean faecal egg counts [31].   
For the diagnosis of S. stercoralis, WHO recommends both the Baermann methods and Koga-agar plates. 
Both methods have only moderate sensitivity, thus a combination of the two methods is often suggested. 
Since both methods take long to perform and require specific equipment, few epidemiological studies are 
conducted and, therefore, few data are available on S. stercoralis prevalence [4,5].   
3.2 Non-direct methods  
3.2.1. Serology  
  
Serology based diagnostic is increasingly used in non-endemic areas for patient evaluation. It allows faster 
diagnosis, being the sample easy to collect and multi-diagnosis possible. Serology can be applied for 
diagnosis of S. stercoralis, when faecal-based methods fail to detect the infection [14]. In the past years 
different serological tests have been evaluated to test the performance in detecting the decline of antibody 
titre after treatment [32]. In areas where re-exposure is excluded, negativization of antibody titre is a better 
indication of cure than negative stool samples [32]. When drug efficacy is tested, the main limitation for 
serology is that the titre takes few months to decrease, which means a long follow-up of the patient is 
needed [32,33]. A difficult situation is when it occurs hyper-infestation in immunosuppressed patients (for 
instance, with HIV/AIDS, taking immunosuppressive therapy or with cancer), in which immune response is 
impaired and false negative results can occur and be misleading [14].   
Serology has also been applied for the detection of other intestinal parasitic infections. Indirect 
hemagglutination (IHA) has been used for the diagnosis of schistosomes with good results [34], reaching a 
sensitivity of 88% for S. mansoni and 80% for S. haematobium with an overall specificity of 95%. Another 
successful application of serologic methods is the enzyme-linked immunosorbent assay (ELISA), which has 
shown good performance (>90% sensitivity) for both species as well as  high specificity (98%) [34]. For the 
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detection of Schistosoma a dipstick that employs a monoclonal antibody against S. mansoni tegumental 
antigen is also available; it has shown good sensitivity and specificity (86.7% and 90%, respectively) 
compared with ELISA sandwich [34].  
3.2.2 CAA and CCA  
A rapid diagnostic test for the S. mansoni diagnosis has recently been developed and tested for accuracy 
and sensitivity in the field against the recommended techniques. This test is based on the detection of 
Circulating  
Cathodic Antigen (CCA) and Circulating Anodic Antigen (CAA) in urine samples described since late ‘70s [35]. 
Importantly, detection of these antigens in either blood or urine is evidence for an ongoing active infection 
as both antigens are subject to rapid renal clearance from the human circulation [35]. Both methods have 
shown a large ranges of both sensitivity (from 39% to 89% for CCA and from 47% to 94% for CAA)  and 
specificity (from 8% to 100% for both methods) when compared with the microscopy considered as “gold 
standard”, which underlines the need of further research [36–38]. One of the limitations of CCA is the risk 
of potential for cross-reaction with other parasite antigens and some human cancers [39,40]. Studies 
conducted on migrants, have shown that a combination of urine CCA and serology tests could find 
application in nonendemic settings, to determine both the previous state of infection and as marker of cure 
if treated [41]. The CAA test is applicable to all Schistosome species, not only to the most common (S. 
mansoni and S. haematobium) [42]. The concentration detected by CAA test is a good proxy on the number 
of worms present in the host. This method is based on luminescent up-converting phosphor reporter 
technology and includes different formats, depending on the matrix and sample volume used for testing 
[42]. In Morocco it was recently adopted on serum to test its accuracy in low-endemic settings [43]. In 
addition, a test conducted in Tanzania showed good results of CAA both on fresh blood samples and dried 
blood spots, being the latter more practical for field handling [44]. Knopp et al evaluated its performance 
on urine samples and results indicated high sensitivity and specificity (97% and 90% respectively) [45]   
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3.3 Molecular diagnosis   
Because of the limited sensitivity of direct methods, the interest towards molecular diagnosis has increased 
lately and different DNA amplification based assays have been developed [34,46–48]. The main problem in 
evaluating molecular techniques is the lack of a “true gold standard” among direct methods [49]. The 
molecular diagnostic techniques are the loop-mediated isothermal amplification (LAMP) and polymerase 
chain reaction (PCR). The main challenge of applying these techniques at a wide scale, is overcoming the 
difficulties in DNA extraction, mainly hindered by the tough egg shell [50]. This fact decreases the sensitivity 
and accuracy of the methods. Furthermore, the presence of high amounts of suspended debris in most of 
the sample matrices impedes nucleic acid extraction and may inhibit PCR reactions [51]. The method of 
choice for DNA extraction varies between studies and depends on the material of the sample, as DNA can 
be extracted from biological samples but also from soil, water, plants, and compost [52]. LAMP is 
characterized by the use of a DNA polymerase that has low sensitivity to inhibitors and comprises a set of 
four primers specially designed to recognize six different sequences on the target gene [52]. The technique 
is based on an isothermal reaction; therefore, it eliminates the need for expensive thermocyclers used in 
conventional PCR. It has been observed that in low resource settings LAMP might be more effective, as it is 
cheaper and more practical to handle, alike a point-of-care diagnostic test with a sensitivity comparable to 
the conventional PCR [52,53]. As an example, in the detection of Taenia spp LAMP performed even better 
than conventional PCR, showing a sensitivity of 88% vs 37% [52].  
PCR is the most used molecular technique in virology and microbiology, whereas its application in 
parasitology is still under development. However, conventional PCR is a non-quantitative technique, so it is 
not useful in settings aiming at evaluating drug efficacy or control of transmission and elimination. There 
are other important limitations of this technique that is worth to be taken into consideration: it is sensitive 
to inhibitors present in the sample, it relies largely on the setting and diet of the population, on sampling 
and collection, on the procedure of pipetting and it is largely operator-dependent [52]. Despite these 
limitations, conventional PCR is the method that changed the diagnostic perspective and improved the 
diagnostic tools for parasitic infections. One of the greatest advantages of PCR is its specificity for a species 
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or group of species, according to the target gene sequences chosen. Moreover, new multiplex PCR has 
developed a high sensitivity at detecting different parasites at the same time, rendering the diagnosis fast 
and efficacious, even if singleplex remains more accurate and sensitive [49]. The targets for amplification 
are multiple, though ribosomal sequences and mitochondrial targets are most  studied because of the 
tandem repeats easily found in eukaryotic cells [54,55]. However, while effective, such diagnostic targets 
are often sub-optimal: highly repetitive DNA elements frequently make up a substantial portion of the 
genome, and are often present at thousands of copy-numbers per haploid genome. Due to such over-
representation, non-coding repetitive sequence elements have become the targets of choice for many PCR-
based diagnostic assays. Realtime quantitative PCR (qPCR) is a step forward from conventional PCR, as it 
allows an accurate count of DNA copies that correlates with egg counts of conventional direct methods. The 
performance of qPCR is still debated, but several studies have shown a good performance of this molecular 
method for intestinal parasites and more accurate results compared to Kato-Katz [47,50,56].   
    
4. Morbidity linked to intestinal and urogenital infections  
Morbidity arising from schistosome and STH infection is defined as complications linked to the primary 
infection of intestinal and urogenital parasites that lead to impairment of health and, therefore, of a 
healthy life. DALYs are usually considered a good indication of morbidities due to the infection [8,9,57]. 
Calculation of an accurate DALY value implies that it is possible to quantify an accurate measure of disease 
impact, as well as an accurate estimate of disease incidence and duration, or of current prevalence which is 
hard to determine for intestinal helminthic infections. STH infections are often asymptomatic or with light 
and unspecific symptoms, which misleads diagnosis and jeopardizes an accurate evaluation of morbidities. 
Acute syndromes are characterised by eosinophilia, cough, urticaria and gastric discomfort [1,15]. Chronic 
infections are also characterized by non-specific symptoms such as diarrhoea, abdominal discomfort, 
anaemia and occult or fresh faecal blood are common accompanied by mucosal haemorrhage, and 
abdominal distension [1,58,59]. S. stercoralis infection is commonly asymptomatic in otherwise healthy 
individuals, or presents mild and systemic symptoms. Hyperinfestation, on the other hand, can be severe 
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and eventually lethal [1,4,60]. Chronic STH infections induce a permanent inflammation which 
compromises growth at different levels: chronic loss of blood, impaired intake, digestion and absorption of 
nutrients  
[59,61–63]. In detail, ascariasis (and trichuriasis in some cases) is associated with low serum vitamin A 
(retinol) by interfering with vitamin A absorption [62]. Moreover, studies on cognitive development have 
been carried out, and showed that STH infections negatively correlate with mental performances [64,65]. 
Children diagnosed with Trichuris Dysentery Syndrome, a severe form of trichuriasis, showed a severe 
decrease in mental and cognitive skills and development compared to the match controls [66–68]. 
Hookworm disease is characterised by moderate-severe iron-deficiency anaemia due to small yet multiple 
hemorrages in the small intestine caused by the worms, which leads to protein and chronic blood loss. A. 
duodenale causes 2-10 folds higher blood losses than N. americanus [69].  
All evidence suggests that morbidity of schistosomiasis is due to the presence of the parasite eggs in tissues 
and not due to the adult worms [12,70]. Not all the eggs produced are excreted; therefore, they are lodged 
in the intestinal or hepatic tissue (S. mansoni, japonicum, intercalatum, mekongi) or in the urogenital 
system (S. haematobium). The eggs induce a granulomatous immune response, which contains egg 
enzymes that avoid tissue necrosis but produce a chronic tissue inflammation [70,71]. This form of the 
disease presents as non-specific intermittent abdominal pain, diarrhoea, and rectal bleeding, with the 
frequency of symptoms often being related to the intensity of infection. Such gastrointestinal features are 
often focal with isolated mucosal hyperplasia, pseudopolyposis, and polyposis interspersed with normal 
bowel [72]. The scarce immunoregulation often leads to extensive fibrosis and hepatosplenic disease with 
periportal fibrosis [71,73]. Clinical features include upper abdominal discomfort with palpable nodular and 
hard hepatomegaly, often with splenomegaly [74]. Ascites and haematemesis from oesophageal varices, a 
complication of portal hypertension, can rapidly lead to death [75]. The time from initial infection to 
advanced fibrosis is usually 5 –15 years [76]. Nonetheless, this clinical feature can be observed in children of 
6 years of age [77], which underlines the importance of screening and periodic treatment. Periportal 
fibrosis is reversible after antischistosomal treatment.   
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The clinical presentation of urogenital schistosomiasis is characterized by persistent haematuria, urinary 
frequency and suprapubic discomfort [78]. As for intestinal schistosomiasis, severe urogenital 
schistosomiasis is a result of poor immunoregulation response to schistosomes-egg, leading to chronic 
fibrosis of urinary tract, presenting as obstructive uropathy up to hydronephrosis. This condition is  a fertile 
field for bacterial superinfection and renal disfunction with potential lethal consequences [79,80]. 
Squamous cell carcinoma of the bladder is also strongly associated with S. haematobium infection [81]. 
Female urogenital schistosomiasis can severely affect fertility. Schistosome eggs lodged in the urogenital 
system induce inflammatory response, that damages the reproductive tract [82]. Unfortunately, treatment 
might not resolve these advanced forms of genital tract damage and there is growing evidence that such 
lesions can increase transmission of HIV [12,83]. For men urogenital schistosomiasis could present with 
haematospermia, orchitis and fertility impairment [84]. These conditions resolve more readily after 
antischistosomal treatment than those of female genital schistosomiasis.   
Similar to STH infections, schistosomiasis has also systemic clinical morbidities such as anaemia (mainly due 
to minimal but chronic bleeding), malnutrition and impaired childhood development, as a result of the 
chronic inflammation status on iron metabolism, physical fitness and cognitive function [64,85,86]. 
Treatment can lessen these symptoms and preventive chemotherapy (PC) is crucial to decrease the onset of 
such severe clinical presentation.   
An important epidemiologic feature common to most helminth infections, with the exception of S. 
strercoralis, is that parasites do not multiply in the host; therefore, morbidity is linked to the intensity of 
infection (worm load) which is proportional to the time and extent of exposure to transmission. Thus, the 
aim of regular treatment is to reduce worm load and control/eliminate morbidity in spite of re-infection, 
while for S. stercoralis the infection must be effectively cured in order to eliminate morbidity.    
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5. Treatment and strategies for control   
5.1 Drugs available   
The benzimidazoles (albendazole and mebendazole) are the mainstay of treatment for the reduction of STH 
prevalence and burden. These drugs have firstly been launched in the ‘80s and still represent the first-
choice regimen for STH treatment. They are administered as single dose in public health interventions. 
Benzimidazoles have excellent safety records and can be administered in both young children and pregnant 
women except from the first trimester. Both drugs have high efficacy against A. lumbricoides, albendazole is 
efficacious against hookworm, but both are less efficacious against T. trichiura [87–89]. Currently, the 
recommended treatment for S. stercoralis infection is single dose ivermectin, which has high efficacy (CR  
>95%). Albendazole administered over three days could be an alternative although it is scarcely efficacious 
[90].  
Praziquantel is the only drug of choice against Schistosoma spp., It is active against adult worms, but has no 
activity against juvenile stages [91]. A standard dose of 40 mg/kg is thought to be effective for treatment of 
S. haematobium and S. mansoni and can safely be used in pregnancy after the first trimester. For other 
species (S. japonicum and S. mekongi), the recommended dose is 60 mg/kg. A dose pole is used in the field 
to determine the number of tablets to use by height  [92].  
A dose pole for pre-school aged children extended below 94 cm is also available since a few years. Cure 
rates are low perhaps because the extrapolation of adults’ dose is not appropriate for children [93–95]. A 
paediatric formulation of praziquantel is under development; currently praziquantel is administered to 
children by crushing tablets in juice to counterbalance the bitter taste of the drug. The evidence collected 
so far from studies conducted on efficacy of praziquantel in pre-school aged children, show a flat dose-
response against S. mansoni infection and the overall efficacy is lower in pre-school than in school-aged 
children [96]. This stress the need of more studies conducted in the paediatric population. Common side 
effects of praziquantel are abdominal pain and cramps, vomiting, headache and dizziness, especially in 
patients with moderate-heavy infections [96].   
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5.2 Preventive chemotherapy   
PC is the regular anthelminthic treatment of in-need populations in endemic areas. This strategy is 
necessary due to the high rate of infection and severe morbidities caused by helminthiasis. In 2012, the 
London Declaration on Neglected Tropical Diseases announced a cross-sectoral commitment by several 
partners, including global partnerships and drug manufacturers, to help eliminate or control preventable 
neglected tropical diseases by 2020, inspired by WHO roadmap targets [2,6,89,97,98]. This commitment 
included a goal of treating 75% of children at risk of STH infections and schistosomiasis in all endemic 
countries. To this end, 600 million doses of albendazole and mebendazole are donated annually by 
pharmaceutical companies, which is enough to treat nearly 70% of the 876 million at-risk children 
worldwide. In 1984, WHO endorsed a strategy of control of morbidities caused by schistosomiasis through 
regular administration of praziquantel. Merck KGaA, (Darmstadt, Germany) is bound to donate 
approximately 250 million tablets of praziquantel per year.   
The main focus of PC are school-aged children (5-14 years old). Current WHO guidelines suggest to widen 
the spectrum and include pre-school-aged children as well in order to tackle morbidities at cognitive and 
physical development stages. PC is distributed through school infrastructures, which has been 
demonstrated to be the most cost-effective strategy to reach such a vast population. Modelling done to 
measure the effects of the programme have erased the idea of extending the coverage to the whole 
population, in order to fight reservoirs (i.e. adults are considered to be a source of transmission for 
hookworm) [99,100]. In fact, the highest the coverage of in-need population, the greater the associated 
benefits in the non-targeted population in terms of reduced prevalence and transmission of infections. 
Although highly efficacious, PC  has limitations that should be addressed and improved in order to maximise 
and sustain its benefits [89,101,102].   
The first limitation is linked to the drugs currently used. PC is based on the administration of a single 
benzimidazole tablet in monotherapy yearly or twice a year in areas endemic for STH, but the cure rate of 
these drugs against STH is poor. Mebendazole has low efficacy against hookworm infections [103,104] and 
both benzimidazoles are ineffective against T. trichiura [87,103,104].   
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Reinfection shortly after treatment is another challenge. Several studies have shown that prevalence and 
intensity of infections, especially for A. lumbricoides and T. trichiura, rapidly (within 4-12 months from 
treatment) reverse back to the pre-treatment status [105–107], while the hookworm reinfection rate is 
lower [108]. In settings were PC is conducted systematically, helminths prevalence and intensity of 
infections decreased [109–111]. Outcomes of PC are different depending on which worm is targeted; for 
instance on Pemba Island, Tanzania, where one of my PhD studies has been conducted, the control 
programme against schistosomiasis started in 1986 [112]. The integrated program of PC and community 
involvement together with snail control [113–116], has been successful and S. haematobium prevalence has 
dropped from 50% to less than 10% [114,117]. On the same trend, it has been shown that there was a 
“collateral benefit” of the ivermectin community-based administration for the elimination of lymphatic 
filariasis on S. stercoralis prevalence, which has dramatically decreased after 6 years of systematic PC [118]. 
On the contrary, on this same island, data on A. lumbricoides and T. trichiura prevalence and intensity of 
infection are not encouraging: despite 20 years of regular PC, T. trichiura prevalence is still above 90% [87] 
and A. lumbricoides above 40% [108].  
Another limitation of the ongoing STH control programmes is the complete lack of intervention against S. 
stercoralis infection, despites the results from recent studies reporting the high prevalence of this infection 
not only in tropical climates but at all latitudes [4,15]. Recent reports have demonstrated that its 
eradication is possible with pharmacological control with ivermectin [119]. A significant decrease of S. 
stercoralis prevalence has been reported, in areas endemic for lymphatic filariasis and onchocerciasis, 
where PC was distributed at community level [118,120].  
Moreover, PC coverage is still lagging behind the 2020 goal: in 2015 it was reported to be 48.3% in PSAC 
and 63.2% in SAC for STH, for schistosomiasis the coverage was 41.8% in SAC and 10.3% in  adults [7]. A 
survey recently conducted on praziquantel coverage in Pemba island, revealed that school- based 
treatment was high (more than 80% of coverage), whereas adult coverage (reflecting also WHO reports [7]) 
was low [101,114,121]. Many factors contribute to low PC coverage, Knopp et al., highlighted some such as 
hard-toreach areas, breastfeeding, pregnancy, absenteeism and community fatigue. The mentioned factors 
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should be taken into consideration when evaluating the state of the art of intestinal helminth control and 
when planning a specific strategy to implement the program, according to local needs and addressing 
constraints [97,114,122,123]. On the other hand, high coverage and frequent treatments , despite averting 
severe morbidity, decreasing rate of infection and transmission, and preventing severe and chronic 
consequences in young population, may have a downside which is represented by the increased danger of 
developing resistance due to high drug pressure [99,124].  
In selected areas, the aim of PC programme is the elimination of the parasite. For example, elimination of 
schistosomiasis has been pursued and obtained in some endemic areas (such as Morocco, Tunisia, China) by 
joining forces between PC and other interventions for interruption of transmission such as vector control 
and water sanitation and hygiene (WASH) [102,116,125–129]. During the first 50 years of large-scale efforts 
to control schistosomiasis, snail control was the primary intervention used to prevent infection, as no drugs 
were suitable for mass distribution [111]. At present PC is the most widely used intervention, and 
molluscicides are applied in selected high-transmission water bodies. The limited application of pesticides is 
mainly due to environmental damages. Niclosamide is a good example, it is non-toxic to people, it kills 
snails at low concentrations, but it is harmful to some freshwater fish and amphibians. The use of this 
compound is licensed in the USA, and when used in suitable habitats, it has been an important contributor 
to schistosomiasis elimination campaigns [130–132]. In schistosomiasis endemic areas, snail control should 
be considered as an integral part of the intervention, especially in high transmission sites 
[99,123,126,127,129]  
Lately, behavioural change is one of the most discussed topics with promising results 
[100,123,125,126,133].  
The implementation of WASH, education and communication programmes should act harmoniously with 
PC. Studies are currently examining data collected from the implementation of PC together with WASH and 
educational approaches [125,126,133]. Results are still controversial, but such integrated interventions will 
have stronger and longer-term impact. Updated WHO guidelines tailored on specific needs would be highly 
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beneficial: for instance, high endemic settings that aim at transmission control, should focus on 
implementing  
PC targeted on PSAC and maybe involving adult population when at high-risk of fresh water contact. In 
contrast, low endemicity settings, that aim at elimination of transmission, should focus on wide arrays of 
interventions, such as PC, WASH, behavioural changes and snail control [97,115,123,125,133–138].  
5.3 Promising drug alternatives   
The research for new drugs and compounds for intestinal parasite infections has languished in the past 
decades; currently, no candidates are in the pipelines of pharmaceutical companies, which could be soon 
put on the market to improve efficacy of existing products or in case resistance against available drugs 
develops [91,103].  
Moxidectin is a macrocyclic lactone derived from the actinomycete Streptomyces cyanogriseus spp. 
noncyanogenus used in veterinary practice against filariasis since the ’90. Considering these promising 
results, it has recently been adopted by human medicine for the treatment of onchocerciasis with good 
results in terms of efficacy against microfilariae and safety profile. Its mechanism of action is still under 
debate, but studies on its pharmacokinetics have demonstrated that it influences the glutamate-gated 
chloride channels and the gamma-aminobutyric acid receptor complex, which, consequently, causes a 
paralysis and death of the parasite [139,140]. Studies conducted on moxidectin pharmacokinetic in humans 
have shown that both liquid and tablet formulation are quickly absorbed [82], are extensively distributed in 
body fluids and have a long half-life [140]. Korth-Bradley et al. have reported an increased bioavailability of 
the drug by the simultaneous consumption of food [141]. Given this scenario, Attah et al. have conducted a 
pilot study to assess the efficacy of moxidectin against the main intestinal parasites (STHs, S. mansoni), with 
encouraging results [142].. Moxidectin was for the above-mentioned reasons, one of the main focus of my 
PhD project.   
Another promising group of drugs are the oxolanes. Oxolanes have been studied as potential alternatives, 
due to their in vitro and in vivo effects against Schistosoma spp. and Clonorchis sinensis [143,144]. In more 
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detail, OZ277 (arterolane maleate) has been shown to be effective against the adult and juvenile stages of 
S. mansoni and S. japonicum [143]. In 2011, arterolane maleate in combination with piperaquine was 
licensed in India (Synriam) for treatment of uncomplicated P. falciparum malaria. Synriam was a drug 
candidate evaluated during my PhD project.   
As mentioned above, one of the main concerns of implementation of PC is the potential occurrence of drug 
resistance. In fact, extensive use of the few drugs available on the market as monotherapy might repeat in 
humans the dramatic  scenario that we are witnessing in veterinary medicine [145–148]. Mathematical 
modelling revealed that the likelihood of resistance development is significantly delayed when drug 
combinations with different modes of action are administered [149–151]. Differently from other fields, such 
as bacteriology and virology, where combination of drugs that act on different pathogen’s targets is a 
longtime established treatment strategy, only few clinical trials have been conducted to explore the efficacy 
of drug combination against helminthic infections [149,150,152,153]. One of the most striking evidence of 
efficacy of the combined treatment of albendazole/oxantel pamoate against T. trichiura infection was 
recently published [87]. This good outcome led the attention to the need of more research into drug 
combinations instead of single drug use. Lately, several trials have been conducted testing the efficacy and 
safety of anthelminthic drug combinations. For example, the co-administration of ivermectin and 
albendazole was revealed to enhance the efficacy of these drugs against T. trichiura and STH coinfections 
[154–156]. Moreover the co-administration of ivermectin and tribendimidine showed a non-inferiority 
efficacy to albendazole/oxantel pamoate against hookworm infections [157].   
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Chapter 2  
Aim and objectives  
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2.1 Aim and objectives  
The main goal of my PhD project was to evaluate the efficacy of new drugs and drug combinations 
against intestinal parasitic infections. Further goals stretched from the application of different 
diagnostic methods and their comparison (DNA extraction methods and PCR protocols) to clinical 
evaluation of urinary tract morbidity in children infected with S. haematobium. The specific 
objectives of my PhD are listed in more detail below:  
1. Efficacy of moxidectin and Synriam® against S. mansoni and S. haematobium infections: to 
determine the efficacy and safety of (i) moxidectin alone and (ii) Synriam® (Arterolane  
(OZ277) and piperaquine) alone and (iii) Synriam®-praziquantel combination compared to 
(iv) praziquantel against S. mansoni and S. haematobium infections (Chapter 4).  
2. Efficacy of moxidectin against S. stercoralis infection: to evaluate the efficacy and safety of 
(i) moxidectin compared to (ii) ivermectin against S. stercoralis infection (and co-infection 
with O. viverrini) (Chapter 5a).  
3. CompareqPCR versus duplicate Baermann method in the diagnosis of S. stercoralis: to 
assess the sensitivity and specificity of two DNA extraction methods analysed with qPCR 
versus duplicate Baermann method in the diagnosis of S. stercoralis (Chapter 5b).  
4. Efficacy of different moxidectin drug combinations against T. trichiura infection: to 
evaluate the efficacy and safety of (i) moxidectin, (ii) moxidectin plus tribendimidine, (iii) 
moxidectin plus albendazole versus (iv) albendazole plus oxantel pamoate against T. 
trichiura infection and concomitant STH infections in adolescents (Chapter 6).  
5. Clinical evaluation of urinary tract morbidity in S. haematobium infected PSAC and SAC : to 
assess the evolution of urinary tract morbidity in S. haematobium infected PSAC and SAC 
six months after treatment with different doses of praziquantel and placebo (control 
group) (Chapter 7).  
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The most recent estimates suggest that between 600 and 800 million people are infected with at least one 
of the common soil-transmitted helminths (STH) [1,2]. Recently, the burden due to STHs has been 
estimated at 1.2-10 million DALYs for A. lumbricoides, 1.8-22.2 million DALYs for T. trichiura and 1.6-6.4 
million DALYs for hookworm [3].   
For A. lumbricoides and T. trichiura, only infections of moderate and heavy intensity are mainly linked to 
morbidity, while for hookworm any intensity of infection may cause morbidity, depending on the iron 
status of the host [3]. Infections are typically most intense and debilitating in SAC and adolescents and 
chronically infected children might suffer from malnutrition, physical and cognitive retardation, and 
reduced work performance in adulthood [4]. The backbone of the preventive chemotherapy (PC) strategy 
to control STH relies on the distribution of a single dose of albendazole or mebendazole, to PSAC, SAC and 
women of childbearing age [5]. In 2016 637.5 million children (PSAC and SAC) received PC; reaching a 
coverage of 50% in PSAC and 69% in SAC. WHO aims at a global coverage of 75% of SAC at risk of morbidity 
from both STH and schistosomiasis by 2020. Pharmaceutical companies support the process by donating 
the benzimidazoles [5]. A meta-analysis recently conducted on the impact of PC on morbidity, linked to STH 
infections, shows that, for all species, the average proportion of moderate-heavy intensities decreases by 
73% after 12 months and by 95% after 130 months of 2 or more PC rounds [3]. Despite the declining trend 
of morbidity and mortality [3,6,7], there is still evidence that linked morbidity is a huge problem [8,9]. Also 
from an economical point of view, estimates have shown that in settings aiming at the control of morbidity, 
PC is highly cost-effective even where the prevalence of STH is below the WHO threshold [10]. These 
considerations drive attention to the need of an attentive re-evaluation of WHO guidelines in terms of 
broadening the coverage spectrum by including low endemicity settings that would also benefit from this 
strategy [10,11].   
The main topic of my PhD project was the evaluation of new drugs and drug combinations against the more 
prevalent intestinal helminth infections. In this context, we selected moxidectin as a good alternative to the 
available drugs. In the first trial, we tested moxidectin in comparison with Synriam against S. mansoni and S. 
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haematobium. Synriam is a new drug on the market for malaria, which might have had efficacy against 
schistosome infection.   
Secondly, in a different study setting, we evaluated the non-inferiority of moxidectin to ivermectin in 
treating S. stercoralis infections. Having a common chemical background, moxidectin was considered a 
potential good weapon against S. stercoralis.   
The third research question was to test the efficacy of moxidectin alone and in co-administration with 
albendazole and tribendimidine vs albendazole plus oxantel-pamoate against T. trichiura and concomitant 
STH infections. This trial was designed to target an important research topic, which are the drawbacks of 
benzimidazoles in treating T. trichiura infections. Tribendimidine and albendazole have been added to 
broaden the spectrum of activity, since moxidectin is known to be scarcely effective against hookworm [12]. 
Another objective was driven by the low sensitivity of current diagnostic methods towards intestinal 
helminthic infections and the rising interest in molecular techniques. We therefore, compared direct 
microscopy-based methods with PCR.   
As already mentioned, one of the targets of PC is to reduce morbidity linked to intestinal parasitic infections 
[5,10,11]; thus, we designed a trial to evaluate the effect of different doses of praziquantel on urinary tract 
morbidity in PSAC and SAC infected with S. haematobium.  
The results of the individual studies have already been discussed within the separate manuscripts, thus, in 
this section of my thesis I would like to focus on three main research themes which I have explored in the 
past three years:  
1) Efficacy of the tested drugs and drug combinations and future steps  
2) Molecular diagnosis: its application in parasitology and future prospective  
3) Evaluation of urinary tract morbidity linked to S. haematobium infection and its response to different 
doses of effective treatment versus placebo  
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8.1 Efficacy of the tested drugs and drug combinations and future 
steps  
Recently, WHO updated the guidelines on PC strategies against STH and schistosome infections [5]. This 
guide should regulate the distribution of treatment to in-need and at-risk population groups. This approach 
is tailored to the specific needs of different settings: from aiming at control of morbidities, to their 
elimination. Large scale distribution of drugs is not based on diagnosis of helminthic infections, but targets 
specific groups such as young children (12-23 months), PSAC (24-59 months of age), SAC (5-12 years of age) 
and pregnant women after the first trimester [5]. The recommended drugs are the benzimidazoles 
(albendazole 400 mg and mebendazole 500 mg) against STH and praziquantel (40 mg/kg) against 
schistosomes. However, a recent meta- analysis, however, confirmed the low efficacy of the benzimidazoles 
especially against T. trichiura and hookworm infections [13].   
Efficacy is measured using the cure rate (CR) and the egg reduction rate (ERR) after treatment; the former is 
based on the proportion of cured individuals who were infected before treatment; the latter is the 
proportional reduction in egg counts after treatment, but the way it is calculated is still under debate. In 
fact, ERR varies depending on whether it is calculated using arithmetic or geometric mean [14]. Both 
methods have limitations mainly due to the fact that egg output is not normally distributed, even after 
logarithmic transformation.   
Geometric mean is used to overcome the dispersion that “outliers” would produce on the mean; geometric 
mean normalizes the variance of the data because it is more interested in the whole population, and 
usually generates an overestimation of the ERR. However, “outliers” in helminthic infections are important, 
since those are the ones who will suffer the most from the morbidity caused by these infections [14–17]. 
On the other side, arithmetic mean is not the ideal indicator either, because the untransformed data cannot 
be analysed with the parametric tests (such as ANOVA) [15]. The two means are only interchangeable for 
ERR>95% [14]. In conclusion, although both means are used in clinical trials and efficacy assessments, both 
parameters are suboptimal measurements [14,17–19]. In fact, for high intensity of infections, geometric 
mean tends to overestimate ERR, the opposite happens for low intensity of infections; therefore, the best 
option to evaluate drug efficacy would be to stratify the analysis by class of intensity of infection [15].   
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Both albendazole and mebendazole are highly active against A. lumbricoides (CR 92-98% and ERR 94-100% 
for both drugs), albendazole has good activity against hookworm (CR 70-85% and ERR 82-97%), but 
mebendazole does not (CR 20-47% and ERR 50-70%). What is most alarming, though, is the confirmed low 
performance of both drugs against T. trichiura with a maximum CR of 60% and ERR of 77% for mebendazole 
and CR of 42% and ERR of 61% for albendazole [13]. Of great interest, is the trend of reduced efficacy of the 
benzimidazoles in the past 20 years against both hookworm and T. trichiura, which may be a sign of 
occurrence of drug resistance in the worm populations [20,21]. Reduced efficacy of praziquantel has also 
been reported in literature in the schistosome population, for S. haematobium ERR ranging from 50% to 
99% and CRs from 65 to 89% have been reported For S. mansoni ERRs from 83 to 99% and CRs ranging from 
26 to  
89% were found [14,22]. An assessment conducted in Uganda, reported a lower efficacy of praziquantel in 
SAC that received higher number of PC rounds than in SAC who received fewer or no rounds of PC, even 
though not statistically significant [23]; ERR in schools with higher PC exposure was 91.5% compared to 
9897% in schools with lower exposure.   
In the framework of my PhD, moxidectin has been evaluated as a potential alternative drug against 
intestinal helminths. The first study setting was Côte d’Ivoire, endemic for both S. mansoni and S. 
haematobium. The trial design was a proof of concept aiming at 30 participants per treatment arm [chapter 
4]. Synriam, a combination of arterolane and mefloquine, alone and in co-administration with praziquantel 
was also evaluated; praziquantel alone was used as comparator [24]. Previous studies have shown a good 
performance of moxidectin against S. mansoni with a CR of around 60% [12]. Also artemisinin derivatives 
have potential antischistosomal activity known since the ‘80s [25]. In vitro and in vivo trioxolanes have 
shown high activity both against juvenile S. mansoni and S. japonicum infections and against the adult 
worm stage in the hamster model [26]. In particular, Synriam, after being licensed in 2011, has been studied 
for its excellent activity against S. mansoni [27].   
Disappointingly, in our trial, these promising data were not confirmed; we observed low efficacy of both 
moxidectin and Synriam against S. haematobium, despite intensity of infections being low. The highest CR 
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and ERR was reached with the co-administration of Synriam and praziquantel (60% and 96%, respectively), 
which suggests an interaction between the two mechanisms of action. Of note, both new drugs tested 
alone performed better against S. mansoni than against S. haematobium in terms of ERR, whereas CRs were 
consistent in both cohorts. In our study the ERR ranged from 87.5% against S. mansoni to 94% against S. 
haematobium with praziquantel alone. These results are consistent considering that the study area is highly 
exposed to PC [23,28]. Until now there is no clear evidence of wide range resistance to the treatment with 
praziquantel [29]. Few isolates of S. mansoni were reported as being resistant [30], but no resistance  was 
reported for S. haematobium yet [31,32]. Nonetheless, in experimental models it has been shown that 
Schistosoma spp  can develop some level of resistance to praziquantel [32]. The topic of praziquantel 
resistance remains an open field for research, since neither  the precise mode of action of the drug, nor the 
genetic bases of schistosomes are completely understood [23,28,33].   
More promising data were collected during my second randomized, phase 2 exploratory trial in which the 
efficacy of moxidectin was compared to that of ivermectin against S. stercoralis infections [chapter 5a]. The 
study was designed as a non-inferiority single blind study. Moxidectin has a similar structure to ivermectin 
and it has been used in macaques against S. fuelleborni infections [34]. As expected, moxidectin showed 
good efficacy in curing S. stercoralis infections, confirming non-inferiority to ivermectin (94 vs. 95%, 
respectively). Despite the great efficacy of ivermectin against S. stercoralis, it is currently the only available 
and highly efficacious drug against this parasite, thus, it is crucial to find alternatives. In fact, in veterinary 
medicine, resistance to ivermectin is a major global problem in the control of gastrointestinal roundworms 
of sheep, cattle and horses. Additionally, there is recent evidence of ivermectin resistance in canine 
heartworm [35]. Concurrently, a reduced effect of ivermectin on human O. volvulus has raised concerns 
that ivermectin resistance might occur also against other helminth species. It is becoming increasingly 
evident that basing control strategies on one single drug (i.e. ivermectin for lymphatic filariasis) is risky and 
no longer sustainable; this also highlights the importance of new, integrated approaches [35]. Resistance 
has also been described towards moxidectin in veterinary medicine, but the molecular patterns are 
different. Prichard et al. have thoroughly described the diversity of the two molecules in pharmacokinetic, 
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this includes a larger volume of distribution, longer elimination half-life and slower clearance rate of 
moxidectin compared with ivermectin [36]. This evidence also hints that the mechanism of action and 
resistance patterns might differ between in ivermectin and moxidectin. Further studies in Caenorhabditis 
elegans on efflux pumps components involved in drug elimination, have clarified the mode of action of both 
drugs. The transporter pumps are ATP-binding cassettes (ABC) which consist of transmembrane proteins 
that use ATP hydrolysis as energy source for the active extrusion of a variety of drugs, carcinogens and 
toxins across the cellular plasma membrane. Pglycoprotein (PgP), Multidrug Resistance associated Proteins 
(MRPs of the ABCC family) and Breast Cancer Resistance Protein (BCRP) are among the best characterized 
drug transporters. These pumps are located in the apical side of the cells of barrier epithelia (intestine, 
placenta, mammary gland and the blood-brain barrier), and participate in the active efflux of different toxic 
compounds out of the cell [36]. Ivermectin and moxidectin, although sharing a similar structure, are not 
identical, with moxidectin showing a weaker affinity for the PgP, having a stronger affinity for BCRP and 
slower efflux out of the organism. These differences allow moxidectin to be effective against ivermectin-
resistant strains [37,38].    
During the above-mentioned trial, we had the opportunity to test the efficacy of moxidectin against 
concomitant O. viverrinii and hookworm infections, being the study site endemic for these parasites.  
Unfortunately, we did not experience any ancillary benefit on the co-infection with O. viverrinii: the CR and 
ERR of moxidectin were 18% and 13%, respectively. Although the reported activity of ivermectin against 
hookworm is low (CR between 11 and 33%) [39–41], we registered a moderate efficacy for moxidectin (CR 
of 57%).   
In the framework of my third clinical trial [Chapter 6], efficacy of moxidectin alone and in co-administration 
with albendazole and tribendimidine against STH was assessed. The first objective of this trial was to 
evaluate the efficacy of those treatments versus the co-administration of albendazole and oxantel-pamoate 
against T. trichuris infection. Until now, the latter formulation is the one that has proved to have the 
highest efficacy against T. trichiura [42]. Our results confirmed the non-inferiority of the co-administration 
of moxidectin/albendazole to albendazole/oxantel pamoate in terms of ERR (98.5% vs 99.8%, respectively), 
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but CR was lower (51% vs 83%, respectively). The co-administration moxidectin/albendazole showed very 
good efficacy against A. lumbricoides infections (both ERR and CR>95%) and against hookworm co-
infections (ERR 93% and CR 77%). This study confirmed that this co-administration is a good alternative to 
the albendazole/oxantel pamoate regimen against STH infection. As for the other co-administration 
(moxidectin/tribendimidine), we reported a fairly good efficacy against T. trichiura in terms of ERR (92%) 
but not in terms of CR (23%). Being tribendimidine a good alternative to benzimidazole for treating 
hookworm, we were not surprised by its good efficacy against hookworm infection both in terms of ERR 
and CR (93% and 88%, respectively). The monotherapy with moxidectin was the least effective drug against 
all STH; it showed high efficacy only against A. lumbricoides. This observation hints for synergistic action 
between moxidectin and the partner drugs. The increased efficacy of moxidectin when administered with 
either albendazole or tribendimidine, suggests a synergistic effect. This synergisms may be explained by the 
pathways of efflux of these drugs [36,37,43] This synergy might be partially explained by looking at the 
mechanism that regulates the excretion of benzimidazoles and macrocyclic lactones. Both groups are 
actively transported by the efflux pump. The PgP is largely expressed in different organs and tissues both of 
humans and parasites and it is involved in the defence of the organisms against toxic compounds, 
therefore, the higher the affinity the faster is a toxin effluxed [36]. Ivermectin has a stronger affinity for the 
PgP than moxidectin [37]. Macrocyclic lactones and the metabolites of benzimidazoles are good substrates 
and inhibitors of the ABC transporters which control the concentration of these drugs by affecting their in 
vivo absorption, distribution, and elimination. Pharmacokinetics studies have shown that drugs have 
different affinity for the different ABC transporters: ivermectin is transported by the PgP[44] and 
albendazole sulfoxide and moxidectin by the BCRP[45]. It has been reported that the inhibition of the ABC 
transporters increases moxidectin bioavailability, raising its plasmatic levels[45]. Since albendazole 
metabolites and moxidectin are transported by the same transporters, it is likely that the competition and 
consequent inhibition of the BRCP transported from one of the two drugs, enhances the bioavailability of 
the other. This mechanism would explain the synergistic action of albendazole and moxidectin when 
administered together and therefore, the better efficacy of the co-administration compared the 
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monotherapy.  What we observed, confirms what has been reported in previous clinical trials, on the better 
efficacy of co-administration of drugs than monotherapy, especially when macrocyclic lactones are 
combined with benzimidazoles [43,46,47]. This data supports additive or synergistic behaviour which 
involves different drug classes: tribendimidine co-administered with ivermectin has shown some synergism 
on STH infection [46] and albendazole/oxantel pamoate performed better than each drug in monotherapy 
against T. trichiura infection [42]. In my first clinical trial on S. haematobium we also experienced a better 
performance of co-administration of Synriam and praziquantel than the monotherapy, which could also 
suggest an interaction between the two drugs; however, this effect was not confirmed for S. mansoni.  
In all trials conducted, moxidectin has proved to be a safe and well tolerated drug. In the first two trials 
[Chapter 4-5a] moxidectin was used as syrup formulation, as tablets were not yet available. A sweetener 
was added to the syrup in order to mask the bitter taste of the drug. Whereas, for the last trial [Chapter 6], 
tablets were manufactured in Basel, Switzerland. In all trials we experienced a good compliance of 
participants, with no episodes of vomiting or refusing to swallow the drug. No severe side effects were 
registered, some mild symptoms (such as headaches or abdominal cramps) were reported, but they 
resolved without intervention.  Despite the vast number of trials and research conducted in the recent 
years on intestinal helminthic infection at different level, many aspects remain unclear and need further 
research. The body of evidence accumulated from data collected in the past three years of my research 
studies, concur to demonstrate that moxidectin is a promising drug for treatment of several infections. It is 
about to be registered for the treatment of Onchocerca volvulus in humans and data have shown that it has 
a good potential against different parasites, other than filariasis. Lately, more attention has been drawn to 
the co-administration of drugs not only to broaden the spectrum of activity, but also to avoid resistance to 
spread. Therefore, the coadministration of moxidectin with albendazole has shown a good efficacy and 
could be used as alternative to the current treatment options. Of course, more trials are needed to further 
explore and confirm the efficacy we obtained.   
During my PhD the safety and efficacy of moxidectin were assessed through trials that, highlighted 
interesting aspects of this drug. The finding of its low efficacy against schistosomes is an important scientific 
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outcome, although disappointing; on the other hand, moxidectin has resulted in a very good efficacy 
against S. stercoralis, which is worthly of further investigations.   
Another interesting aspect of moxidectin is the dose-dependent effect; we only used 8 mg (or 8 ml) as 
standard dose, but a higher dosage could elicit better efficacy. For example, despite the excellent efficacy 
profile reported by Speich et al. [42] for oxantel pamoate, the co-administration with albendazole reached 
high levels of CR after conducting a dose-finding study [48]. Dose-finding studies are important to fine tune 
the treatment regimen once the drug has proved to be efficacious and safe. Thus, it could be that 
moxidectin would also benefit from a higher dose regimen, especially against STH infections.   
Another interesting aspect is the synergism of moxidectin with the benzimidazoles that, in our study, we 
could only verify at a clinical and drug efficacy level. It would be interesting to deepen the knowledge at 
laboratory level, with pharmacokinetic studies, that could better elucidate the interaction of different drugs 
with efflux pumps and metabolic enzymes.   
    
8.2 Molecular diagnosis: its application in parasitology and future 
prospective  
S. stercoralis is known to be the neglected of the neglected tropical diseases, which is mainly due to the 
scarcity of data on its prevalence and morbidity [49,50]. Despite being always considered a tropical disease, 
recent migration flows and increased travels to endemic areas, have changed the geographical distribution 
on many parasites, including S. stercoralis [51,52]. As mentioned before, an accurate diagnosis, is highly 
relevant for all intestinal helmintic infections, however it is particularly relevant for S. stercoralis as it is the 
only intestinal helminth that replicates within the human host prolonging the infection for years, if not 
properly cured. This peculiarity allows the parasite to persist in old people, in areas where it is no longer 
present, but was once endemic. The diagnosis is burdened by many issues: infections are often 
asymptomatic or lightly symptomatic, diagnostic techniques used for STH fail to detect S. stercoralis, and 
the few methods that detect the larvae have low sensitivity [52–57]. Direct methods, such those 
recommended by WHO  (Baermann and Koga Agar culture), are the only techniques used in endemic 
countries, yet they are timeconsuming and show scarce to moderate sensitivity [58,59]. Furthermore, their 
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performance requires resources (specific incubator, stable source of power, funnels, tubes and enough 
space in the laboratory for incubation), which are crucial for the good outcome of the results [60–62].   
Serology has been proved to be a good alternative, but it is not applicable in high endemicity settings due to 
the long time needed to decrease the antibody titers after treatment [63].   
Molecular techniques are starting to be considered for diagnosis also in parasitology, even if their 
application is still limited to high-resource settings [59,60]. The detection of S. stercoralis might greatly 
benefit from PCR methods, as larvae output is not regular, and up to seven samples are needed in order to 
reach a sensitivity of 100% with microscopy [64]. Moreover, often the intensity of infections is low and 
microscopy fails to detect it. PCR for S. stercoralis is still under development [58,65] and results are 
discordant on PCR performance [65,66]. The main limitation of this method, is related to the DNA 
extraction protocol which is still not standardized; different research groups are working to find the most 
suitable protocol [66].   
In my trial on efficacy of moxidectin against S. stercoralis infection, subsamples of the first collected stool 
sample were preserved in ethanol and shipped to the Swiss TPH for PCR analysis [Chapter 5b]. We 
compared two extraction methods: QIAamp Stool Mini kit (Qiagen; Hilden, Germany) following the 
manufacturer protocol and the QIAamp DNA Mini Kit with a modified protocol according to Polley et al. 
[67]. To avoid adding too many variables in the study, we used the same primers for both extraction 
protocols to perform PCR, although different primers are reported in literature [60,68,69].  
When analyzing the results, the major problem encountered, was that, in the absence of a “true gold 
standard”, it was difficult to estimate the sensitivity of the techniques. Therefore, we assessed sensitivity 
and specificity of the methods comparing results of the two extraction methods and one Bearmann to the 
results of 2 days of Baermann (being the WHO recommended technique) and all techniques to any positive 
sample found by any of the three methods. Surprisingly the two DNA extraction methods did not perform 
similarly; in fact, the standard QIA method showed a sensitivity of 27% compared to Baermann and 31% to 
any positive found. As mentioned above, controversial results on the performance of QIA Stool Mini kit 
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protocol were reported in published literature, with either higher and lower sensitivity when compared to 
microscopy [58,59,68,70].   
The modified protocol performed much better with a sensitivity of 80%; still, the Baermann method on two 
samples collected over two days was the best method and reached the highest score in terms of sensitivity. 
Although our study was not quantitative, we have seen a later positivisation of PCR for Baermann negative 
samples, which hints to a correlation between larvae quantity and PCR detection.   
We confirmed that PCR protocols are still to be improved, as many of the published data rely on in-house 
protocols, that are not yet standardized [66]. In contrast with Repetto et al. [66], but in line with other 
studies, we did not experience a striking improvement in sensitivity of PCR compared to coprological 
methods, and we can confirm that, at present, PCR is still insufficiently sensitive to replace microscopy 
[58,59,68].   
Of note, the combination of the modified extraction method and a single Baermann increases the sensitivity 
to almost 100%. This allows the detection of all positive samples in one day of collection. This would 
significantly simplify field work, especially when working with adolescents and/or adults, who often fail to 
provide more than one sample. Moreover, it has already been reported that PCR performs well on a single 
sample and no consecutive samples are needed to increase the accuracy of the technique [59,71,72]. As 
suggested elsewhere, a combination of PCR and microscopy would be ideal to increase sensitivity 
[59,68,69]. This combined approach would, nonetheless, have important drawbacks (i.e. time-consuming, 
specific and sometimes expensive equipment) that still limit its application on the field and would fail to 
simplify and fasten its performance.   
Molecular techniques are already widely applied in many fields of infection diseases [73–75] and their 
extension to parasitology is needed. Currently, protocols are not standardized and fail to meet the 
expectancies in term of better sensitivity compared to copro-microscopic techniques. As demonstrated also 
with my study, the path to a standardized, sensitive PCR protocol is still long; debates and incongruities 
show up early on even during the very first step of DNA extraction. We can conclude that further research 
in the diagnostic field is needed and a standardized procedure would allow useful comparison among trials.   
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8.3 Evaluation of urinary tract morbidity linked to S. haematobium 
infection and its response to different doses of effective treatment 
vs placebo  
One of my PhD projects focused on the ultrasonographical evaluation of urinary tract morbidity in PSAC and 
SAC infected with S. haematobium before and after treatment. S. haematobium eggs trapped in the tissue 
trigger a constant inflammatory reaction and lead to the formation of granulomas. This results in collagen 
deposition and laminated fibrous tissue replacement of the healthy tissues of the urinary tract, causing 
morbidity [76]. Indeed, schistosomiasis is linked to systemic morbidity, such as anaemia, malnutrition and 
organ complications. The most severe cases of S. haematobium lead to bladder and ureteral dysfunction, 
such as ureteral reflux, hydronephrosis, renal impairment and bladder cancer [77,78].   
Urinary schistosomiasis is widely spread in Africa, affecting mainly children [79]. The goal of PC programs is 
to control morbidity in childhood, in order to prevent organ failure and growth impairment [5]. Even in low 
intensity and chronic infections, sequelae may still be found; most bladder pathology heals after treatment, 
but urinary tract dilatation frequently persists even in successfully treated patients [80]. In recent years 
there have been improvements in the detection of urinary tract morbidity in older children and adult 
population [81]. However, diagnosis of the target population is not commonly performed and relies mostly 
on indirect signs of organ impairment or questionnaire administered to the older population [79]. 
Measuring the burden of infection in endemic populations and the impact of treatment, would be of great 
importance in order to assess the effectiveness of control programmes and, thus, formulate future 
evidence-based control policies.  Point-of-care ultrasonographic evaluation, is becoming a widely used 
diagnostic tool which has been recognized and standardized for fast diagnosis, as well as an integrated  part 
of diagnostic algorithm in emergency medicine [82]. Ultrasonography for evaluation of S. haematobium 
morbidity has been reported to be a “simple-to-learn” examination [83].   
In the framework of a dose-finding clinical trial for praziquantel, in which PSAC and SAC were randomly 
assigned to different doses of praziquantel (20, 40, 60 mg/kg) or placebo, participants underwent an 
ultrasonographic evaluation of the urinary tract. The same children were re-examined 6 months after 
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treatment. Concomitantly, a urine filtration for the diagnosis of S. haematobium and urine dipstick test was 
performed for each child, to look for infection and linked morbidity detectable at point-of-care level. Of the 
infected children, the vast majority (60% of PSAC and 76% of SAC) had microhematuria. Proteinuria was 
present in 40% of PSAC and in 75% of SAC. These results, reveal a high level of organ impairment already in 
younger children. As expected, after treatment, we observed a high prevalence of infection in the placebo 
group (64% in PSAC and 80% in SAC). Also, in the different dose-groups, CRs were quite low with no clear 
indication on which dose has the highest efficacy, especially among SAC. However, all treatment arms 
showed good efficacy in terms of ERR, with almost all high intensity infections cleared or at least reduced 
after treatment; we also experienced an improvement in proteinuria, which dropped below 10% in both 
PSAC and SAC.   
The main focus of my trial was the ultrasonography assessment, which revealed alarming data on the 
prevalence of urinary tract morbidity even in PSAC. Almost half of PSAC (43%) had light to moderate 
bladder morbidity, characterized mainly by focal wall thickening or bladder heterogeneously echoic. Only a 
few of the PSAC had polyps or masses in the bladder (2%) and hydronephrosis (7%). The picture of SAC was 
even more alarming, with 67% of children presenting bladder morbidity. Yet, similarly to PSAC; in SAC the 
pathology was not severe, as only 4% had masses or polyps. A significant correlation (p<0.005) with urine 
analysis was reported for haematuria, leukocyturia and intensity of infection.   
The most interesting finding of the trial, was a significantly positive (p<0.005) correlation between 
treatment and the reversal of S. haematobium induced morbidity. Surprisingly, however, we did not 
experience a better performance of higher doses of praziquantel which suggests a non-linear correlation 
between increase of drug dose and reverse of morbidity. In treated groups, we observed an improvement 
of the clinical picture in 90% of children; in both PSAC and SAC the progression of morbidity was inversely 
proportional to treatment dose. On the other hand, in the placebo group, we reported a small proportion 
(13%, both in PSAC and SAC) of spontaneous reversal of morbidity and a big proportion (40% in PSAC and 
60% in SAC) of progression of urinary tract morbidity.  
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These data highlight the importance of regular treatment. In fact, early complications of the infection are 
quantifiable with ultranosography, and, if not treated, this infection can lead to severe organ failure 
[76,78,84,85]. Moreover, we reported an improvement in urine analysis in treated children, which mirrors a 
general improvement of urinary tract morbidity consequent to praziquantel.   
Based on published literature and our results, we can conclude that the extension of PC to PSAC is crucial to 
prevent early urinary tract morbidity in S. haematobium infected children, especially in areas where 
endemicity and reinfection rates are high.    
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Chapter 9  
  
Conclusions  
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In the frame of this PhD thesis, we analysed few innovative issues within the control of intestinal helminthic 
infections. More specifically, we conducted four clinical trials in which we had the opportunity to explore 
several aspects of intestinal helminthiases, such as diagnosis, morbidity linked to infection and different 
treatment options.   
We have found moxidectin to be a good alternative option for the treatment of S. stercoralis in endemic 
setting and confirmed its good safety profile. Regarding schistosomiasis, the previously described 
antischistosomal effect of moxidectin, was not confirmed in our study. On the other hand, we proved the 
efficacy of the co-administration of moxidectin and albendazole against T. trichiura and its non-inferiority 
against the best available option (albendazole/oxantel pamoate). Moxidectin with albendazole has also 
proved to be effective against hookworm and A. lumbricoides; these results indicate that this combination 
may find application in areas endemic for STH and S. stercoralis. Therefore, moxidectin in co-administration 
with albendazole is worth of further evaluations with dose-finding and pharmacokinetic studies to be 
conducted, which will hopefully clarify the mechanism of action of the two drugs.   
On the diagnostic side, we have highlighted difficulties in S. stercoralis detection; copro-microscopic 
techniques, although time-consuming and cumbersome have revealed a better performance than novel 
molecular tools. Therefore, further research is needed to improve DNA extraction to optimize PCR 
application for the diagnosis of this parasite.  
Finally, we confirmed the early onset of urinary tract morbidity linked to S. haematobium infection, which 
already affects young children. The ultra-sonographic evaluation before and after treatment with 
praziquantel allowed us to highlight the importance of regular treatment for the regression of urinary tract 
morbidity, and consequently also highlighting the relevance of ultrasound as monitoring tool as well as the 
crucial impact of PC on control of morbidity in S. haematobium infected children.   
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